Kornimate/medical-research-clean huggingface dataset:
assess safety, bio-distribution, radiation dosimetry and optimize the imaging protocol of geh120714 (18f) injection in healthy volunteers and participants with relapsing and remitting multiple sclerosis (rrms).

Conditions: Relapsing-remitting Multiple Sclerosis (rrMS)

Summary: to evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the imaging protocol of geh120714 (18f) injection. study recruits healthy volunteers and participants with relapsing and remitting multiple sclerosis.


Eligibility criteria:
inclusion criteria: inclusion criteria for all participants: * the subject has a clinically normal or acceptable medical history and physical examination at screening. * the subject has an acceptable kidney function (egfr \>60 ml/min/1.73m2) for administration of gadolinium. * the subject has a trans-locator protein (tspo) platelet assay conducted with documented results. inclusion criteria for all healthy volunteers: * the subject has no clinical history or signs of neurological impairment. * the subject has a normal mri without central white white matter lesions. inclusion criteria specific for participants with relapsing and remitting results sclerosis (rrms): * subject with a previous diagnosis of rrms, presenting with (a) clinically active disease at time of screening or, or preferentially, (b) clinically active disease at time of screening and having at least one gadolinium--enhanced lesion on mri. * the subject at screening has a mri scan of sufficient quality for volume of interest (voi) definition and co-alignment with positron emission tomography (pet). exclusion criteria: general exclusion criteria for all participants: * the subject has a contraindication for magnetic resonance imaging (mri). * the subject has known allergies to gadolinium contrast agent. * the subject has received significant ionising radiation exposure from clinical trials or medical examinations in the last 12 months. exclusion criteria specific for healthy volunteers: * the subject has family history of multiple sclerosis (ms). * the subject is undergoing monitoring of occupational ionising radiation exposure. exclusion criteria specific for participants with remitting multiple sclerosis (rrms): * the subject has a past history of cerebrovascular disease or vasculitis. * the subject has a history of head injury with prolonged coma.
identifying genetic determinants of eczema herpeticum and other viral infections in individuals with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: people with atopic dermatitis (ad), or eczema, are susceptible to skin infections and inflammations. some individuals with ad develop a condition known as eczema herpeticum (eh) following exposure to the herpes simplex virus (hsv). the purpose of this study is to identify the genetic determinants that lead people with ad to develop eh and similar conditions caused by other viruses.

ad is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. however, people with ad do not all develop the same infections. for example, some people with ad who receive the smallpox vaccine develop a life-threatening condition known as eczema vaccinatum (ev). this study focuses on individuals with ad who also have a history of eczema herpeticum (adeh+), a condition similar to ev. it is unlikely that the differences in the development of skin infections are due to differences in viral exposure, and instead due to differences in each individual's response to viruses. the purpose of this study is to determine the genetic pathways which are responsible for the development of viral skin infections in people with ad. participants in this study will also be enrolled in the advn biomarker registry study. there will be only one clinical visit for this study at which blood and/or skin samples may be collected. the samples will then have high-throughput genotyping to define genetic markers in individuals susceptible to viral infections.

Eligibility criteria:
inclusion criteria: * enrollment in advn biomarker registry study * non-hispanic and only african american or only caucasian race * parent or guardian willing to provide informed consent, if necessary exclusion criteria: * history of any systemic illness, excluding ad * participation of a first degree relative already enrolled in the genotyping study unless the subject in question fulfills the diagnostic criteria for adeh+. more information on this criterion can be found in the protocol.

Keywords: atopic dermatitis eczema eczema herpeticum molluscum contagiousum herpes simplex vaccinia
diagnostic performance of a commercial assay for the detection of neuronal antibodies

Conditions: Paraneoplastic Neurological Syndrome; Autoimmune Encephalitis

Summary: detection of autoantibodies targeting neuronal surface or intracellular antigens is a keystone for the diagnosis and the treatment of auto-immune encephalitis and paraneoplastic neurological syndromes. a strategy commonly used for their detection is to perform a screening with a tissue-based immunofluorescence assay or immunohistochemistry assay and a second line test to confirm and identify the autoantibody. since several years, commercial kits are used by a growing number of laboratories to screen the presence of these autoantibodies. however, the diagnostic performance of these commercial kits is highly variable and several studies reported a high prevalence of false-positive and false-negative results with commercial immunodots and cell-based assays. it is therefore essential to explore commercial kits limitations in order to avoid false-positive and false-negative results that could lead to misdiagnosis and/or to delay the treatments. to assess the diagnostic performance of commercial kits, the investigators performed a prospective study in which the investigators screened patients neuronal autoantibodies in cerebrospinal fluid and sera using commercial tissue-based indirect immunofluorescence assay and cbas in comparison with an in-house tissue-based indirect immunofluorescence assay.


Eligibility criteria:
* inclusion criteria \* : sera and/or csf with sufficient volume to perform both in-house and commercial assays * exclusion criteria \* : sera and/or csf with insufficient volume to perform both in-house and commercial assays

Keywords: autoantibodies diagnostic paraneoplastic encephalitis neuronal
vr and cooled genicular nerve radio frequency ablation for chronic knee pain

Conditions: Pain, Chronic

Summary: this study will examine the impact of virtual reality used in conjunction with sedation compared to sedation alone in patients undergoing watervcooled genicular nerve ablations for chronic knee pain. the goals of the study is to determine the relative efficacy of virtual reality as a distraction modality when used as an adjuvant to procedural sedation compared to sedation alone for procedure related pain. to assess procedural satisfaction, and 1-month pain and functional outcomes.to explore whether virtual reality and lower procedure-related pain scores affect 1-month outcomes. and finally to determine whether demographic and clinical characteristics are associated with outcome measures.


Eligibility criteria:
inclusion criteria: * patients undergoing genicular rfa will be eligible for inclusion in the study * patients with knee pain, baseline average of \> 4/10 * x-ray evidence of osteoarthritis of the knee * pain duration of \>6 weeks and no previous knee surgeries * patients will also only be included who have never undergone a rfa on the affected knee exclusion criteria: * individuals who do not have evidence of osteoarthritis on x-ray, * secondary gain expected to influence treatment outcomes * poorly controlled psychiatric condition that could affect outcome (e.g. active substance abuse) or impose a barrier to participation * chronic opioid use and anticoagulation therapy that cannot be stopped and could warrant a different treatment approach (e.g. phenol ablation) * severe motion sickness * seizure disorder * vision loss * pregnant * nursing

Keywords: pain knee pain virtual reality radio frequency ablation genicular nerve block
a single ascending dose study of bms-650032 in hcv infected subjects

Conditions: Chronic Hepatitis C

Summary: the primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of bms-650032 in subjects with chronic hepatitis c infection


Eligibility criteria:
inclusion criteria: * chronically infected with hcv genotype 1 * treatment naive or treatment non-responders or treatment intolerant * hcv rna viral load of ≥10\*5 iu/ml * bmi 18 to 35kg/m² exclusion criteria: * any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with hcv infection * major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug * co-infection with hiv or hbv * women of childbearing potential
a study evaluating bemarituzumab in combination with other anti-cancer therapies in subjects with previously untreated advanced gastric or gastroesophageal junction cancer.

Conditions: Gastric Cancer; Gastroesophageal Junction Cancer

Summary: the main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with s-1 and oxaliplatin (sox) and nivolumab as assessed by objective response.


Eligibility criteria:
inclusion criteria: * adults with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer not amendable to curative therapy. * ability to provide tumor sample, either archival (obtained within 6 months to joining study) or fresh biopsy. * for certain arms for part 1, fgfr2b overexpression positive defined as any fgfr2b 2+/3+ tc determined by centrally performed immunohistochemistry (ihc), based on tumor sample provided. * for part 2, fgfr2b overexpression positive defined as fgfr2b ≥10% 2+/3+ tc determined by centrally performed ihc testing, based on tumor sample provided. * easter cooperative oncology group (ecog) performance score less than or equal to 1. * measurable or non-measurable disease as long as evaluable by response evaluation criteria solid tumors (recist) version 1.1 * participant has no contradictions to capox/sox plus or minus nivolumab. * adequate organ function. * for part 2, measurable disease according to recist v1.1. exclusion criteria: * prior treatment for metastatic or unresectable disease (note: prior adjuvant or neo-adjuvant therapy for local disease is allowed if ended more than 6 months of 1st dose). * prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (fgf-fgfr) pathway. * known human epidermal growth factor receptor 2 (her2) positive * untreated or symptomatic central nervous system (cns) disease or brain metastases. * peripheral sensory neuropathy greater than or equal to grade 2. * clinically significant cardiac disease. * other malignancy within the last 2 years (exceptions for definitively treated disease). * chronic or systemic ophthalmological disorders. * major surgery or other investigational study within 28 days of first study treatment dose. * palliative radiotherapy within 14 days of first study treatment dose. * abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer. * history or evidence of systemic disease or ophthalmological disorders requiring chronic use of ophthalmic corticosteroids.

Keywords: gastric cancer gastroesophageal junction cancer bemarituzumab fgfr2b overexpression
r-epoch in combination with ibrutinib for patients with classical rt of cll

Conditions: Richter Transformation

Summary: this is an investigator-initiated phase 2 study, which combines r-edoch with ibrutinib to treat patients with ritcher transformation in consideration of dlbcl and cll components both could being targeted at the same time. the investigator will observe the 2-year overall survival rate of this regimen for rt and explore the new regimen for rt in the novel drugs era, which aims to improve the efficacy and prolong survival.


Eligibility criteria:
inclusion criteria: 1. age 18-65 years 2. ecog 0-2 3. confirmed richter transformation, whether or not previously treated 4. unexposed to btki, or discontinue btki more than 1 year (due not to toxicity or ineffectiveness) 5. no serious liver, kidney, heart and other complications; including: a. alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 3 times the upper limit of normal (uln); b. total bilirubin (tbil) ≤ 1.5 times the uln; c. serum creatinine (cr) ≤ 2 times the uln, or glomerular filtration rate ≥ 40ml/min; d. lvef \> 50% determined by echocardiography; e. no arrhythmia and active heart disease, such as coronary heart disease, myocardial infarction, etc 6. the patient agreed to participate and signed the informed consent form exclusion criteria: 1. major surgery within 4 weeks prior to first dose of ibrutinib 2. require receiving anticoagulation with warfarin or equivalent vitamin k antagonists; requires treatment with a strong cyp3a4/5 inhibitor 3. require corticosteroid , anti-cancer drugs, immunomodulatory or chinese medicine for other medical conditions 4. pregnant or lactating women 5. history of prior malignancy 6. currently active clinically significant cardiovascular disease 7. uncontrolled active systemic fungal, bacterial, viral, or other infection 8. known history of human immunodeficiency virus (hiv) or active infection with hepatitis b or hepatitis c 9. history of stroke or intracranial hemorrhage prior to randomization 10. other conditions that is unfit for the clinical trial in the investigator' opinion

Keywords: richter transformation chronic lymphocytic leukemia r-epoch ibrutinib therapeutics
ptgs1 genetic variation and increased risk for persistent pulmonary hypertension of the newborn

Conditions: Persistent Pulmonary Hypertension of the Newborn

Summary: the purpose of this study is to determine if normally occurring variations in a specific gene called ptgs-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (nsaids).

persistent pulmonary hypertension of the newborn (pphn) occurs when the pulmonary vascular resistance fails to decrease at birth during the transition to postnatal life. the affected infants have severe hypoxemia, a 10% risk of mortality, and among survivors, a 30% incidence of long term neurodevelopmental and hearing deficits. the etiology of pphn in the majority of affected infants remains unknown. although constriction of fetal ductus arteriosus in response to maternal intake of non-steroidal anti-inflammatory drugs (nsaid) has been implicated in pphn case reports, our laboratory was the first to provide objective evidence for such an association. nearly 87% of infants with pphn were exposed to nsaid in utero. yet 25% of control infants also were exposed without developing pphn. the basis for the biological susceptibility of some neonates to in utero nsaid exposure remains poorly understood. the hypothesis of this proposal is that ptgs1 genetic variation is associated with increased susceptibility to ductal constriction from in utero nsaid exposure and an increased risk of pphn. this hypothesis will be tested through the following specific aims: determine the incidence of ptgs1 sequence variants in pphn patients versus matched controls. ptgs1 sequence will include all 11 exons, a minimum of 100 bp of exon flanking sequences, and 1 kbp of upstream regulatory information. cycle sequencing will be performed followed by analysis using capillary electrophoresis. differences in the frequency of sequence variants will be determined using fisher's exact test. the study will also quantify nsaid exposure in meconium samples using a previously established gc/ms assay and correlate exposure levels to both the incidence of pphn and the presence or absence of ptgs1 sequence variants using regression analysis. benefits include the ability to predict risk for pphn based on ptgs1 sequence and avoidance of such risk in the future, thereby reducing patient morbidity and mortality.

Eligibility criteria:
inclusion criteria: * infants born greater than or equal to 34 weeks gestational age diagnosed with pphn and normal, healthy infants born greater than or equal to 34 weeks gestational age. exclusion criteria: * patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (pda) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, potter's syndrome, or pulmonary hypoplasia

Keywords: pphn ptgs1 nsaid
associations of exposure to phthalates with insulin resistance and epigenetic change

Conditions: Insulin Resistance; Decreased Pulmonary Function

Summary: * phthalate is an endocrine disrupting chemical, which works as an anti-androgenic agent. * phthalate is mainly used as pvc plasticizer and easily found in commonly used products such as electronic device, paint, lubricant, surfactant, medical supplies, spray etc. especially, pvc blood bag used for blood transfusion have been reported to have high level of phthalate concentration. * previous studies reported that urinary concentration of phthalate metabolites and homa (homeostatic model assessment, indicator of insulin resistance) has positive association. * previous studies also reported negative associations between urinary phthalate concentration and pulmonary function. * exposure to phthalates occurs mainly through oral route. food wrapping with phthalate containing package material is expected to be one of the major contributor for phthalate exposure. * in this present trial, the investigators are to examine whether increased phthalate exposure by consuming beverage stored in pvc containing packing materials actually effect insulin resistance, pulmonary function and epigenetic feature. * for this aim, the investigators will conduct a cross-over trial.


Eligibility criteria:
inclusion criteria: * participants who understand aim of this study and who provided informed consent exclusion criteria: * who did not provided informed consent * person who are undergoing or planning to take a treatment due to liver, nervous system, respiratory system, hematologic, oncologic, psychiatric, cardiovascular(angina pectoris, myocardial infarction, stroke etc), endocrinal(diabetes mellitus, thyroid disease) disorders.

Keywords: insulin resistance pulmonary function phthalates
safety, tolerability, pharmacokinetics and preliminary efficacy of av411 in neuropathic pain

Conditions: Diabetic Neuropathy

Summary: the purpose of this study is to determine the safety, tolerability and pharmacokinetics of av411 after single and multiple doses in patients with chronic neuropathic pain due to diabetes.


Eligibility criteria:
inclusion criteria: * diagnosis of diabetic neuropathy or complex regional pain syndrome of at least 6 months duration * vas score of 4 cm or higher at screening * no clinical abnormality in laboratory and urine analyses * electrocardiogram within normal limits at screening * negative pregnancy test on study day 1 for female subjects of childbearing potential * on stable doses of medications, analgesic or others for at least 8 weeks prior to study enrollment * willing to use barrier contraceptive during the period of the study exclusion criteria: * known hypersensitivity to av411 or its components * conditions which might affect drug absorption, metabolism or excretion * untreated mental illness, current drug addiction or abuse or alcoholism * donated blood in the past 90 days or have poor peripheral venous access * platelets \<100,000mm3 or a history of thrombocytopenia * known or suspected chronic liver disease * gfr \<=90ml/min/1.73m2 (cockcroft-gault) * female subjects who are pregnant or nursing mothers * received an investigational drug in the past 90 days * unable to swallow large capsules
registry study of thoracic reirradiation for non-small cell lung cancer (nsclc) utilizing proton beam therapy or intensity modulated radiation therapy

Conditions: Non-Small Cell Lung Cancer

Summary: the goal of this research study is to learn more about the safety of treating nsclc with reirradiation using standard methods and to look for ways to lessen side effects and improve therapy. reirradiation is when radiation is given to an area of the body that has previously received a full dose of radiation.

if you agree to take part in this study, data will be recorded during your therapy. the data to be recorded will include your medical history, the disease, treatments you have received and how you have responded to any treatments, as well as any side effects you may have had. the data will be stored on a password-protected computer at md anderson for use in future research related to cancer. your data will be given a code number. no identifying information will be directly linked to your data. only the researcher in charge of this study will have access to the code numbers and be able to link the data to you. this is to allow medical information related to your data to be updated as needed. other researchers using your data will not be able to link this data to you. length of study: after you sign this consent form, your active participation on this study will be over. this is an investigational study. up to 120 patients will take part in this study. all will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. history of previous histologically or cytologically documented nsclc, stage i-iv. 2. prior course of radiation therapy or concurrent chemoradiation at least 1 month prior to the current course of radiation therapy. 3. patients eligible to receive a second course of radiation therapy to the thorax, at the discretion of the treating physician. 4. patients receiving concurrent chemotherapy or targeted agents will be eligible for this protocol. 3.2 exclusion criteria: 1. life expectancy\<3 months 2. pregnancy.

Keywords: non-small cell lung cancer nsclc thoracic reirradiation proton beam therapy pbt intensity modulated radiation therapy imrt registry data
prospective evaluation of forceplate measured levodopa-induced dyskinesia

Conditions: Parkinson's Disease

Summary: nearly all parkinson's disease (pd) patients eventually develop abnormal and unwanted movements (dyskinesias; lid) caused by the gold standard treatment, levodopa. the severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. the purpose of this study is to demonstrate the validity and reliability of objectively measuring dyskinesia with a forceplate.

the main outcome measure of this study are measurements taken every half hour during an inpatient study visit. these measurements include standing on a forceplate for 1 minute while performing a mental task such as reciting the alphabet backwards. during this forceplate stance, a rater will visually score your movements. all participants must be eligible for another parkinson's disease study at oregon health and science university.

Eligibility criteria:
inclusion criteria: * parkinsons disease * older than 18 exclusion criteria: * must be participating in a parkinsons disease study at oregon health \& science university

Keywords: parkinsons disease dyskinesia measurement